Analgesic and anti-inflammatory effects of some benzanilides

PubMedID: 2788215Analgesic and anti-inflammatory effects of N-(p-ethoxyphenyl)-2,6-dihydroxybenzamide (1), N-(p-ethoxyphenyl)-2,6-diacetoxybenzamide (2), N-(p-ethoxyphenyl)-2,5-dihydroxybenzamide (3), and N-(p-ethoxyphenyl)-2,5-diacetoxybenzamide (4) have been investigated in mice and rats. The analgesic effect of 2 on acetic acid-induced writhing was found to be stronger than that of aspirin, whereas that of 1, 3, and 4 was weaker than that of aspirin. In inflammatory studies, 1—4 showed inhibition of formaldehyde-induced paw swelling (edema). The effects of 1—3 were more potent than that of aspirin, 1 being the most potent. The potency of 4 was almost equal to that of aspirin. Copyright © 1989 Wiley-Liss, Inc., A Wiley Compan

Frequency analysis of low flows in intermittent and non-intermittent rivers from hydrological basins in Turkey

This study attempts to find out the best-fit probability distribution function to low flows using the up-to-date data of intermittent and non-intermittent rivers in four hydrological basins from different regions in Turkey. Frequency analysis of D ¼ 1-, 7-, 14-, 30-, 90- and 273-day low flows calculated from the daily flow time series of each stream gauge was performed. Weibull (W2), Gamma (G2), Generalized Extreme Value (GEV) and Log-Normal (LN2) are selected among the 2-parameter probability distribution functions together with the Weibull (W3), Gamma (G3) and Log-Normal (LN3) from the 3-parameter probability distribution function family. Selected probability distribution functions are checked for their suitability to fit each D-day low flow sequence. LN3 mostly conforms to low flows by being the best-fit among the selected probability distribution functions in three out of four hydrological basins while W3 fits low flows in one basin. With the use of the best-fit probability distribution function, the low flow-duration-frequency curves are determined, which have the ability to provide the end-users with any D-day low flow discharge of any given return period. © 2019 IWA Publishing. All rights reserved

Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: Posttreatment 1-year results of three Turkish centres

PubMed ID: 24171823In this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2.9% and 60.2%, whereas 1-year sustained virological response rates were 0 and 33.3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P50.028; Mann–Whitney U test, P50.023). Overall non-response rates to PEGIFN were high (57.1%). Results in HBeAg-positive cases were disappointing. © 2014 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia